Literature DB >> 25945734

Erbb4 Signaling: an overlooked backup system?

Yingjia Ni1, Siyuan Zhang.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25945734      PMCID： PMC4614367          DOI： 10.1080/15384101.2015.1032653

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

Review 1.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

2.  Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

Authors:  Denis Tvorogov; Maria Sundvall; Kari Kurppa; Maija Hollmén; Susanna Repo; Mark S Johnson; Klaus Elenius
Journal:  J Biol Chem       Date:  2008-12-19       Impact factor: 5.157

Review 3.  Targeting HER2 for the treatment of breast cancer.

Authors:  Mothaffar F Rimawi; Rachel Schiff; C Kent Osborne
Journal:  Annu Rev Med       Date:  2015       Impact factor: 13.739

4.  Regulation of survivin by ErbB2 signaling: therapeutic implications for ErbB2-overexpressing breast cancers.

Authors:  Wenle Xia; John Bisi; Jay Strum; Leihua Liu; Kevin Carrick; Katherine M Graham; Amanda L Treece; Mary Ann Hardwicke; Michael Dush; Qiaoyin Liao; Ron E Westlund; Sumin Zhao; Sarah Bacus; Neil L Spector
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

5.  Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.

Authors:  Kaleigh Canfield; Jiaqi Li; Owen M Wilkins; Meghan M Morrison; Matthew Ung; Wendy Wells; Charlotte R Williams; Karen T Liby; Detlef Vullhorst; Andres Buonanno; Huizhong Hu; Rachel Schiff; Rebecca S Cook; Manabu Kurokawa
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 6.  Treatment strategy for HER2-positive breast cancer.

Authors:  Hirofumi Mukai
Journal:  Int J Clin Oncol       Date:  2010-07-15       Impact factor: 3.402

Review 7.  ERBB2 oncogene in human breast cancer and its clinical significance.

Authors:  F Révillion; J Bonneterre; J P Peyrat
Journal:  Eur J Cancer       Date:  1998-05       Impact factor: 9.162
  7 in total
  1 in total

1.  Methylation-associated silencing of miR-193a-3p promotes ovarian cancer aggressiveness by targeting GRB7 and MAPK/ERK pathways.

Authors:  Kangmei Chen; Michelle Xin Liu; Celia Sze-Ling Mak; Mingo Ming-Ho Yung; Thomas Ho-Yin Leung; Dakang Xu; Siew-Fei Ngu; Karen Kar-Loen Chan; Huijuan Yang; Hextan Yuen-Sheung Ngan; David Wai Chan
Journal:  Theranostics       Date:  2018-01-01       Impact factor: 11.556
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.